OBJECTIVE： To observe the effect of rosuvastatin on prognostic of patients with paroxysmal atrial fibrillation （AF） after circumferential pulmonary vein ablation. METHODS： 75 patients with paroxysmal AF were divided into observation group （n＝39） and control group （n＝36） according to the admission single. All patients underwent circumferential pulmonary vein ablation antiarrhythmic treatment. Control group orally received warfarin sodium， amiodarone， metoprolol， and subcutaneous injected low molecular weight heparin. Observation group additionally received 10 mg Rosuvastatin tablet， qd on the basic of contol group. Changes of cardiac function， inflammatory factors， lipid levels in 2 groups before and after treatment were observed， and follow-up results were compared. RESULTS： There was no significant difference in left atrial diameter and left ventricular ejection fraction in 2 groups before and after treatment （P＞0.05）； atrial effective refractory periods （AERP） in 2 groups significantly prolorged， and observation group prolorged more significantly than control group， the difference was statistically significant （P＜0.05）. Serum high sensitivity C-reactive protein， interleukin-6 48 h and 1 month after operation in 2 groups significantly increased， and control group was significantly higher than observation group， the difference was statistically significant （P＜0.05）； before operation and after 3 months of operation， there was no significant difference in inflammatory cytokine levels （P＞0.05）. Triglyceride and low density lipoprotein cholesterol  in observation group 1 month after operation significantly decreased， HDL-C significantly increased， there were significant differences （P＜0.05）. Follow-up time was （23.91±5.28） months， AF recurrence was 7.8％， which was significantly lower than control group （13.9％）， the difference was statistically significant （P＜0.05）； and there were no significant differences in ablation-related atrial tachycardia （ATa） and the incidence of adverse reactions between 2 groups （P＞0.05）. CONCLUSIONS： Rosuvastatin can effectively inhibit the inflammatory reaction and prolong the AERP， thereby reducing the recurrence rate of AF， with good efficacy and safety.